TO THE EDITOR-We read the article by Fraaij et al [1] and would like to summarize the available information on intravenous zanamivir from the Food and Drug Administration (FDA)'s Emergency Investigational New Drug (EIND) application process [2] . No intravenous antiviral agents for treatment of severe influenza are currently approved in the United States. Since the emergence of 2009 pandemic influenza A virus subtype H1N1 (A[H1N1]pdm09), intravenous zanamivir has been authorized through an EIND application to the FDA as an investigational treatment for patients with serious and life-threatening influenza. As part of the EIND process, treating physicians are encouraged to submit data to the FDA, but reporting of requested data is voluntary. We reviewed the FDA's EIND database on influenza patients who received intravenous zanamivir from April 2009 through April 2011. For the 200 patients identified, we performed a descriptive analysis of reported patient information on age, sex, pregnancy status, baseline comorbidities, virologic test results, antiviral resistance data, other antiviral treatments, clinical complications, supportive care modalities used, intravenous zanamivir treatment duration, adverse events (AEs), and outcomes (Table 1) .
At the time of intravenous zanamivir request, many patients were critically ill with underlying comorbidities and required intensive care unit admission for severe complications of influenza A virus infection ( predominantly due to A[H1N1]pdm09), including respiratory failure and renal failure. Most patients (9) (78.5%) had received prior or concomitant antiviral agents, mainly oseltamivir, although some (10%) had also received intravenous peramivir. Nine percent of patients (mostly with comorbidities and/ or immunosuppression) had documented oseltamivir resistance associated with the H275Y mutation in viral neuraminidase, and overall approximately 25% of intravenous zanamivir requests were for patients with confirmed or clinically suspected oseltamivir resistance. Other published case series of A(H1N1) pdm09-infected patients have reported fewer complications at the time of intravenous zanamivir initiation and fewer reports of oseltamivir resistance [1, [3] [4] [5] [6] [7] .
Our findings have several important limitations. First, almost no microbiologic data were provided in cases in which patient narratives reported pneumonia or bacterial coinfection. In 69 of 73 cases reporting pneumonia, microbiologic or additional clinical data were not available to determine whether cases of pneumonia represented secondary bacterial infection or primary influenza virus pneumonitis. In 4 pneumonia cases, methicillin-resistant Staphylococcus aureus (MRSA) infection (in 3 cases) or Pneumocystis jirovecii infection (in 1 case) was reported. In 15 of 19 cases reporting bacterial coinfection, microbiologic or additional clinical data were not provided to delineate the source (eg, blood, urine, skin, central nervous system, or catheter related), etiology, or severity of the bacterial infection. Four cases had microbiologic or clinical information in which MRSA bacteremia (in 3 cases) or Streptococcus pyogenes skin and soft-tissue infection (in 1 case with concomitant burns) was reported. Second, limited outcome, follow-up, or adverse event data were reported. Third, interpretation of data is limited by the retrospective and uncontrolled design to assess differences in data reported (eg, clinical outcomes, microbiologic data, diagnostic data, and adverse events).
Most intravenous zanamivir EIND authorizations were for late treatment of critically ill adult patients with A(H1N1) pdm09 infection, including a subset with confirmed or suspected oseltamivir resistance. It is possible that cases of oseltamivir resistance could increase in the future [8, 9] . However, conclusions Abbreviation: HIV, human immunodeficiency virus. a Renal transplantation (n = 6), lung transplantation (n = 3), congenital immunodeficiency (n = 4), chronic use of steroids (n = 2), and rheumatoid arthritis with chronic use of tumor necrosis factor blocker (n = 2). b All had received oseltamivir.
c Cancer (n = 8), renal transplantation (n = 1), lung transplantation (n = 1), and congenital immunodeficiency (n = 1). d Cancer (n = 8), renal transplantation (n = 2), chronic use of steroids (n = 1), and rheumatoid arthritis with chronic use of tumor necrosis factor blocker (n = 1). e Eighteen also previously received oseltamivir, and 2 received IV peramivir only.
f Five also received oseltamivir, and 3 patients received inhaled zanamivir only.
g One also received oseltamivir, 1 also received IV peramivir, and 1 received oral amantadine only.
h All also received oseltamivir.
i Few EIND narratives reported microbiologic data.
regarding the clinical effectiveness or safety of intravenous zanamivir for treatment of critically ill influenza patients cannot be drawn from these data; randomized clinical trials are needed and are ongoing [10] .
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